URML-3881, a Novel MEK Inhibitor for the Treatment of Cancers

Provided herein, are compounds, compositions, and methods of treatment of cancers using an inhibitor of MAPK/ERK Kinase (MEK), in particular hydrazine derivatives.

URV Reference Number: 6-18073
Patent Information:
Category(s):
Therapeutic
For Information, Contact:
Weimin Kaufman
Licensing Manager
University of Rochester
585.276.6608
weimin.kaufman@rochester.edu
Inventors:
Richard Moore
Rakesh Singh
Rachael Turner
Kyu Kwang Kim
Negar Khazan
Keywords: